AR002707A1 - THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES. - Google Patents
THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES.Info
- Publication number
- AR002707A1 AR002707A1 ARP960101382A AR10138296A AR002707A1 AR 002707 A1 AR002707 A1 AR 002707A1 AR P960101382 A ARP960101382 A AR P960101382A AR 10138296 A AR10138296 A AR 10138296A AR 002707 A1 AR002707 A1 AR 002707A1
- Authority
- AR
- Argentina
- Prior art keywords
- vertebral
- fractures
- reduce
- alendronate
- novertebral
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cuando se administra diariamente por un período de tiempo substancial, el alendronato, un bisfosfonato, puede reducir la tasa de fracturas vertebrales yno- vertebrales en mujeres post-menopáusicas. Además, puede reducir el número y severidad delas fracturas. También, la administración de aledronato puedeprevenir la deformación columnar y la pérdida de altura.When administered daily for a substantial period of time, alendronate, a bisphosphonate, can reduce the rate of vertebral and non-vertebral fractures in postmenopausal women. In addition, it can reduce the number and severity of fractures. Also, the administration of aledronate can prevent columnar deformation and loss of height.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39046295A | 1995-02-17 | 1995-02-17 | |
US08/389,860 US20010051616A1 (en) | 1995-02-17 | 1995-02-17 | Method of lessening the risk of vertebral fractures |
US41963195A | 1995-04-10 | 1995-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR002707A1 true AR002707A1 (en) | 1998-04-29 |
Family
ID=27409915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101382A AR002707A1 (en) | 1995-02-17 | 1996-02-14 | THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES. |
Country Status (9)
Country | Link |
---|---|
AR (1) | AR002707A1 (en) |
CO (1) | CO4920257A1 (en) |
CZ (1) | CZ259097A3 (en) |
DZ (1) | DZ1991A1 (en) |
HR (1) | HRP960080A2 (en) |
IL (1) | IL117077A (en) |
PE (1) | PE46197A1 (en) |
TW (1) | TW453880B (en) |
YU (1) | YU8896A (en) |
-
1996
- 1996-02-08 IL IL11707796A patent/IL117077A/en unknown
- 1996-02-12 PE PE00009596A patent/PE46197A1/en not_active Application Discontinuation
- 1996-02-13 CZ CZ972590A patent/CZ259097A3/en unknown
- 1996-02-14 DZ DZ960032A patent/DZ1991A1/en active
- 1996-02-14 AR ARP960101382A patent/AR002707A1/en not_active Application Discontinuation
- 1996-02-15 CO CO96007058A patent/CO4920257A1/en unknown
- 1996-02-16 YU YU8896A patent/YU8896A/en unknown
- 1996-02-16 HR HRP960080 patent/HRP960080A2/en not_active Application Discontinuation
- 1996-02-28 TW TW085102340A patent/TW453880B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL117077A0 (en) | 1996-06-18 |
IL117077A (en) | 2002-08-14 |
YU8896A (en) | 1999-12-27 |
TW453880B (en) | 2001-09-11 |
PE46197A1 (en) | 1997-11-28 |
HRP960080A2 (en) | 1997-10-31 |
DZ1991A1 (en) | 2002-07-20 |
CZ259097A3 (en) | 1997-11-12 |
CO4920257A1 (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY100721A (en) | Therapeutic agent. | |
ITRM930591A0 (en) | MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR DRUGS AT VERY LOW DOSES, IN PARTICULAR HOMEOPATHIC DRUGS. | |
AU4449789A (en) | Delivery system for pharmaceutical or therapeutic actives | |
ES2190244T3 (en) | USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES. | |
BR9609645A (en) | Inhaler for drug administration from ampoule packs | |
ES2170069T3 (en) | 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION. | |
ATE231719T1 (en) | NEW PHARMACEUTICAL FORMULATIONS | |
HUP0001914A3 (en) | Biocompatible compounds for pharmaceutical drug delivery systems | |
RU94032150A (en) | Medicinal agent exhibiting delayed release of active-acting substance | |
ES554169A0 (en) | METHOD OF MANUFACTURING A MEDICAL DEVICE FOR THE ADMINISTRATION OF A FAT-INSOLUBLE, HIGHLY IONIZED DRUG. | |
IS2537B (en) | Medicinal product for intravenous administration | |
ATE424810T1 (en) | A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER | |
AU2084801A (en) | Antiviral medication | |
ES2159362T3 (en) | USE OF 1- (2-NAFT-2-ILETIL) -4- (3-TRIFLUOROMETILFENIL) -1,2,3,6-TETRAHYDROPIRIDINE FOR THE PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS. | |
ES2010466A6 (en) | Effervescent tablet containing diclofenac | |
AR002707A1 (en) | THE USE OF ALENDRONATE OR AN ACCEPTABLE PHARMACEUTICAL SALT TO PREPARE A MEDICATION USEFUL TO REDUCE THE RISK OF VERTEBRAL OR NOVERTEBRAL FRACTURES. | |
BR9608392A (en) | Multiparticulate controlled-release preparation and tablet dosage form. | |
AR011437A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MIGRANES AND THE USE OF THE SAME IN THE PREPARATION OF A MEDICINAL PRODUCT. | |
ATE150004T1 (en) | TILIDINE DIHYDROGEN ORTHOPHOSPHATE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | |
ZA963714B (en) | Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours. | |
ATE234096T1 (en) | PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION CONTAINING THE ACTIVE INGREDIENT MORPHINE-6-GLUCURONIDE | |
ES2152865A1 (en) | Use of bisphosphonates in pharmaceutical preparations intended for intramuscular use | |
PT1144420E (en) | PHOSPHATIDILINOSITOIS SULPHATATED TO ITS PREPARATION AND ITS UTILIZATION | |
ECSP961665A (en) | METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES | |
AU5981200A (en) | Transdermal therapeutic system for administering a calcium antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |